Acute severe ulcerative colitis: Timing is everything

Postgraduate Medical Journal

Volumn 87, Issue 1025, 2011, Pages 215-222

  Gulliford, Stephen R ^a   Limdi, Jimmy K ^a  

^a PENNINE ACUTE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXUMAB; BETA INTERFERON; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE ANTIBODY; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHYLPREDNISOLONE; PHOSPHATIDYLCHOLINE; PREDNISOLONE; TACROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; VISILIXUMAB;

ABDOMINAL ABSCESS; ABDOMINAL RADIOGRAPHY; ANAPHYLAXIS; BACTEREMIA; BLOOD PRESSURE REGULATION; CLOSTRIDIUM DIFFICILE; COLON BIOPSY; COLON DILATATION; COLON FISTULA; COLON MOTILITY; COLON POUCH; COLON RESECTION; COMPUTED TOMOGRAPHIC COLONOGRAPHY; CONTINUOUS INFUSION; DEATH; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; FECES ANALYSIS; FOLLOW UP; GINGIVITIS; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPOMAGNESEMIA; ILEITIS; LOW DRUG DOSE; MONOTHERAPY; NEPHROTOXICITY; NUTRITIONAL ASSESSMENT; OPEN STUDY; PATIENT SAFETY; PNEUMOCYSTOSIS; PROCTOCOLECTOMY; RECTUM HEMORRHAGE; REVIEW; SEIZURE; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; STEROID THERAPY; SURGICAL MORTALITY; SURGICAL RISK; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ACUTE DISEASE; COLECTOMY; COLITIS, ULCERATIVE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 79952281473     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2010.107029     Document Type: Review

References (72)

1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361:2066-78.
2. Rubin GP, Hungin AP, Kelly PJ, et al. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther 2000;14:1553-9. (Pubitemid 32011728)
3. Solberg IC, Lygren I, Jahnsen J, et al; IBSEN Study Group. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009;44:431-40.
4. Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci 1993;38:1137-46.
5. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2:1041-8.
6. Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501-23.
7. Travis SPL, Stange EF, Lemman M, et al. European evidence based consensus on the management of ulcerative colitis: current management. J Crohn's Colitis 2008;2:24-62. (Pubitemid 351179488)
8. Roberts SE, Williams JG, Yeates D, et al. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn's disease: record linkage studies. BMJ 2007;335:1033.
9. Sonnenberg A. Time trends of mortality from Crohn's disease and ulcerative colitis. Int J Epidemiol 2007;36:890-9. (Pubitemid 47394159)
10. Maher MM, Nassar MI. Acute cytomegalovirus infection is a risk factor in refractory and complicated inflammatory bowel disease. Dig Dis Sci 2009;54:2456-62.
11. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007;13:1545-53.
12. Dickinson RJ, Ashton MG, Axon AT, et al. Controlled trial of intravenous hyper alimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology 1980;79:1199-204. (Pubitemid 11250460)
13. McIntyre PB, Powell-Tuck J, Wood SR, et al. Controlled trial of bowel rest in the treatment of severe acute colitis. Gut 1986;27:481-5. (Pubitemid 16079746)
14. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010;375:657-63.
15. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986;27:1210-12. (Pubitemid 16002622)
16. Mantzaris GJ, Petraki K, Archavlis E, et al. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 2001;36:971-4. (Pubitemid 32681462)
17. Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007;5:103-10. (Pubitemid 46096828)
18. Lennard-Jones JE, Ritchie JK, Hilder W, et al. Assessment of severity in colitis: a preliminary study. Gut 1975;16:579-84.
19. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-10. (Pubitemid 26231777)
20. Lindgren SC, Flood LM, Kilander AF, et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998;10:831-5. (Pubitemid 28493257)
21. Ho GT, Mowat C, Goddard CJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004;19:1079-87. (Pubitemid 38703520)
22. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5. (Pubitemid 24188135)
23. García-López S, Gomollón-García F, Pérez-Gisbert J. Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol Hepatol 2005;28:607-14. (Pubitemid 43117349)
24. Durai D, Hawthorne AB. Review article: how and when to use ciclosporin in ulcerative colitis. Aliment Pharmacol Ther 2005;22:907-16. (Pubitemid 41634871)
25. Shibolet O, Regushevskaya E, Brezis M, et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005;(1):CD004277.
26. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001;120:1323-9. (Pubitemid 32322305)
27. Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125:1025-31. (Pubitemid 37193449)
28. Rayner CK, McCormack G, Emmanuel AV, et al. Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis. Aliment Pharmacol Ther 2003;18:303-8. (Pubitemid 37046709)
29. Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 2005;17:79-84. (Pubitemid 40128931)
30. Actis GC, Fadda M, David E, et al. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol 2007;7:13.
31. Shah SB, Parekh NK, Hanauer SB, et al. Intravenous cyclosporine in severe steroid refractory ulcerative colitis: long term follow up. Gastroenterology 2008;134(Suppl 1):133 [1041].
32. Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006;4:760-5. (Pubitemid 43833506)
33. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999;94:1587-92. (Pubitemid 29260450)
34. Cacheux W, Seksik P, Lemann M, et al. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol 2008;103:637-42. (Pubitemid 351405993)
35. Cullen G, Keegan D, O'Donoghue D. Safety and efficacy of cyclosporine therapy in inflammatory bowel disease. Am J Gastroenterol 2008;103:2654-5.
36. Arts J, D'Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004;10:73-8. (Pubitemid 38332164)
37. Sternthal MB, Murphy SJ, George J, et al. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am J Gastroenterol 2008;103:937-43. (Pubitemid 351501092)
38. Kornbluth A, Present DH, Lichtiger S, et al. Cyclosporin for severe ulcerative colitis: a user's guide. Am J Gastroenterol 1997;92:1424-8. (Pubitemid 27412859)
39. Haslam N, Hearing SD, Probert CS. Audit of cyclosporin use in inflammatory bowel disease: limited benefits, numerous side-effects. Eur J Gastroenterol Hepatol 2000;12:657-60. (Pubitemid 30433543)
40. Actis GC, Aimo G, Priolo G, et al. Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflamm Bowel Dis 1998;4:276-9. (Pubitemid 128699866)
41. Navazo L, Salata H, Morales S, et al. Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis. Scand J Gastroenterol 2001;36:610-14. (Pubitemid 32424252)
42. Weber A, Fein F, Koch S, et al. Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (Neoral). Inflamm Bowel Dis 2006;12:1131-5. (Pubitemid 44847470)
43. Hyde GM, Jewell DP, Kettlewell MG, et al. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. Dis Colon Rectum 2001;44:1436-40. (Pubitemid 32952547)
44. Pinna-Pintor M, Arese P, Bona R, et al. Severe steroid-unresponsive ulcerative colitis: outcomes of restorative proctocolectomy in patients undergoing cyclosporin treatment. Dis Colon Rectum 2000;43:609-13.
45. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006;55:1255-62. (Pubitemid 44277355)
46. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. (Pubitemid 41770166)
47. Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11. (Pubitemid 40824691)
48. Lees CW, Heys D, Ho GT, et al. Scottish Society of Gastroenterology Infliximab Group. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 2007;26:411-19.
49. Kohn A, Daperno M, Armuzzi A, et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther 2007;26:747-56. (Pubitemid 47246204)
50. Jakobovits SL, Jewell DP, Travis SP. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmacol Ther 2007;25:1055-60.
51. Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 2007;13:123-8. (Pubitemid 46806219)
52. Gisbert JP, González-Lama Y, Maté J. Systematic review: Infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007;25:19-37. (Pubitemid 44902861)
53. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004;99:878-83. (Pubitemid 39090217)
54. Marchal L, D'Haens G, Van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther 2004;19:749-54. (Pubitemid 38496640)
55. Appau KA, Fazio VW, Shen B, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg. 2008;12:1738-44.
56. Kunitake H, Hodin R, Shellito PC, et al. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg 2008;12:1730-6.
57. Schluender SJ, Ippoliti A, Dubinsky M, et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum 2007;50:1747-53.
58. Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 2007;204:956-62. (Pubitemid 46661200)
59. Maser EA, Deconda D, Lichtiger S, et al. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol 2008;6:1112-16.
60. Teeuwen PH, Stommel MW, Bremers AJ, et al. Colectomy in patients with acute colitis: a systematic review. J Gastrointest Surg 2009;13:676-86.
61. Loftus EV Jr, Delgado DJ, Friedman HS, et al. Colectomy and the incidence of postsurgical complications among ulcerative colitis patients with private health insurance in the United States. Am J Gastroenterol 2008;103:1737-45.
62. Meagher AP, Farouk R, Dozois RR, et al. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg 1998;85:800-3. (Pubitemid 28300513)
63. Berndtsson I, Lindholm E, Oresland T, et al. Long-term outcome after ileal pouch-anal anastomosis: function and health-related quality of life. Dis Colon Rectum 2007;50:1545-52. (Pubitemid 47583339)
64. Waljee A, Waljee J, Morris AM, et al. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut 2006;55:1575-80. (Pubitemid 44629206)
65. Creed TJ, Norman MR, Probert CS, et al. Basilixumab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003;18:65-75. (Pubitemid 36897982)
66. Creed TJ, Probert CS, Norman MN, et al; BASBUC INVESTIGATORS. Basilixumab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther 2006;23:1435-42.
67. Plevy S, Salzberg B, Van Assche G, et al. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 2007;133:1414-22. (Pubitemid 350029746)
68. Barta Z, Tóth L, Zeher M. Pulse cyclophosphamide therapy for inflammatory bowel disease. World J Gastroenterol 2006;12:1278-80.
69. Lazzerini M, Martelossi S, Marchetti F, et al. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. Aliment Pharmacol Ther 2007;25:419-27. (Pubitemid 46184455)
70. Musch E, Andus T, Malek M, et al. Successful treatment of steroid refractory active ulcerative colitis with natural interferon-beta-an open long-term trial. Z Gastroenterol 2007;45:1235-40.
71. Stremmel W, Ehehalt R, Autschbach F, et al. Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial. Ann Intern Med 2007;147:603-10. (Pubitemid 351664479)
72. Aoki H, Nakamura K, Yoshimatsu Y, et al. Adacolumn selective leukocyte adsorption apheresis in patients with active ulcerative colitis: clinical efficacy, effects on plasma IL-8, and expression of Toll-like receptor 2 on granulocytes. Dig Dis Sci 2007;52:1427-33. (Pubitemid 46776491)